Omnicell, Inc. (NASDAQ:OMCL) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Omnicell, Inc. has received an average recommendation of "Moderate Buy" from analysts, with four buy recommendations and three holds.
• The company's stock has a 1-year price objective set at an average of $45.33 according to broker ratings.
• Omnicell reported $0.45 earnings per share (EPS) for the last quarter, surpassing analysts' expectations of $0.30, with revenue of $290.56 million.

Shares of Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $46.7143.

A number of research analysts have weighed in on the stock. Piper Sandler set a $55.00 price objective on shares of Omnicell and gave the company an "overweight" rating in a report on Monday. Bank of America boosted their price target on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Wells Fargo & Company boosted their target price on shares of Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a report on Monday, July 21st. Benchmark decreased their target price on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, Wall Street Zen downgraded shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th.

Omnicell Stock Up 0.5%

OMCL traded up $0.15 during trading on Monday, hitting $31.49. The stock had a trading volume of 167,751 shares, compared to its average volume of 565,197. The company has a market capitalization of $1.45 billion, a PE ratio of 62.85, a PEG ratio of 9.20 and a beta of 0.78. Omnicell has a twelve month low of $22.66 and a twelve month high of $55.74. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42. The stock has a 50 day simple moving average of $29.43 and a two-hundred day simple moving average of $32.52.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The firm had revenue of $290.56 million during the quarter, compared to analysts' expectations of $275.57 million. During the same quarter last year, the company posted $0.51 earnings per share. The firm's revenue was up 5.0% compared to the same quarter last year. On average, research analysts predict that Omnicell will post 1.09 earnings per share for the current year.

Institutional Investors Weigh In On Omnicell

A number of large investors have recently modified their holdings of the company. Johnson Financial Group Inc. purchased a new position in shares of Omnicell in the 4th quarter valued at $37,000. GAMMA Investing LLC increased its holdings in shares of Omnicell by 37.1% in the 2nd quarter. GAMMA Investing LLC now owns 1,694 shares of the company's stock valued at $50,000 after purchasing an additional 458 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in shares of Omnicell in the 4th quarter valued at about $101,000. Corton Capital Inc. purchased a new position in shares of Omnicell in the 4th quarter valued at about $208,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Omnicell in the 2nd quarter valued at about $210,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.